American College of Emergency Physicians
Clinical Policies Committee Meeting
January 30 and February 5, 2024
Zoom Meeting

MINUTES

Participants

Committee members participating in all or part of the meeting: Deborah B. Diercks, MD, MSc, FACEP, Chair; John D. Anderson, MD, FACEP; Richard Byyny, MD, MSc, FACEP, Methodologist; Christopher R. Carpenter MD, MSc, FACEP; John T. Finnell, MD, FACEP, FACMI, ACEP Board Liaison; Benjamin Friedman, MD, FACEP, Methodologist; Seth R. Gemme, MD, FACEP; Charles J Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Benjamin W. Hatten, MD, MPH, FACEP; Jason S. Haukoos, MD, MSc, FACEP, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Heemun Kwok, MD, MS, FACEP, Methodologist; Amal Mattu, MD, FACEP; Susan B. Promes, MD, MBA, FACEP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Scott M. Silvers, MD, FACEP; Andrea Slivinski, RN, DNP, ENA Representative; Michael D. Smith, MD, MBA, FACEP; Molly E.W. Thiessen, MD, FACEP; John T. Thompson, MD, EMRA Representative; Stacy A. Trent, MD, MPH, Methodologist; Jonathan H. Valente, MD, FACEP; Stephan P. Wall, MD, MSc, MAEd, FACEP, Methodologist; Lauren M. Westafer, DO, MPH, MS, FACEP; Yanling Yu, PhD, Advocate for Patient Safety.

Also present for all or part of the meeting: Peter Panagos, MD, FACEP, Writing Committee on Thrombolitics; Christopher R. Sampson, MD, FACEP; Writing Committee on Seizures; Travis Schulz, MLS, AHIP, Staff Liaison; Kaeli Vandertulip, MSLS, MBA, AHIP, Staff Liaison.

Agenda

1. Welcome and introductions
2. Disclosures pertinent to the agenda
3. Subcommittee and liaison reports
4. EMRA guideline update
5. Seizures clinical policy
6. Thrombolitics clinical policy
7. Methodology paper
8. Asymptomatic hypertension clinical policy
9. Critical questions for cardiac reperfusion clinical policy

Major Points Discussed

1. Welcome and introductions
   Dr. Diercks welcomed everyone to the meeting. Participants introduced themselves.

2. New disclosures pertinent to the agenda
   There were no new disclosures pertinent to the agenda.
3. Subcommittee and liaison reports

Dr. Godwin provided an update on the airway clinical policy.

Dr. Promes provided an update on her work with the American College of Cardiology/American Heart Association writing group on acute pulmonary embolism.

Dr. Anderson provided an update on the early pregnancy clinical policy.

Dr. Silvers provided an update on the venous thromboembolism clinical policy and his work with the American Heart Association/ Emergency Cardiovascular Care Committee.

4. EMRA guideline update

Dr. Thompson provided the committee with a summary of the guideline “British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical investigation and management of pyrexia of unknown origin 2023”.

5. Seizures clinical policy

Dr. Smith, with assistance from Dr. Sampson, led the committee members in a final review of the clinical policy on seizures and the comments received during the 60-day open comment period. The committee recommended the addition of a table containing the medications and dosing cited in the literature reviewed. The writing committee will incorporate the revisions into the draft, and it will be presented to the Clinical Policies Committee for review.

6. Thrombolytics clinical policy

Dr. Lo, with assistance from Dr. Carpenter and Dr. Panagos, led the committee in a review of the first draft of the thrombolytics clinical policy. Committee members suggested several edits to the draft. The writing committee will incorporate the revisions into the draft, and it will be presented to the Clinical Policies Committee for further review.

7. Methodology paper

Drs. Carpenter, Haukoos, and Hatten informed the committee of their plan to draft a paper outlining the approach the methodologists take to critically appraise literature selected to inform clinical policy recommendations. The paper will be based on a manuscript drafted by a former committee member that was submitted to the *Annals of Emergency Medicine* but was not accepted. It is anticipated that this paper will be submitted to *JACEP Open* when complete.

8. Asymptomatic hypertension clinical policy

Dr. Gemme led the committee in a review of the first draft of the asymptomatic hypertension clinical policy. Committee members suggested several edits to the draft. The writing committee will incorporate the revisions into the draft, and it will be presented to the Clinical Policies Committee for further review.
9. Critical questions for cardiac reperfusion clinical policy

Dr. Valente led the committee in a review of the proposed critical questions for the clinical policy on cardiac reperfusion. After considerable discussion, it was decided the writing committee will refine/refocus the questions to areas where the emergency physician is at greatest risk for malpractice. Upon refinement, the critical questions will be presented to the Clinical Policies Committee for further review.


Dr. Diercks led the discussion regarding the ACEP Board of Director’s request for a recommendation on the advisability of implementing the resolution and potential initiatives to address the resolution. Several approaches were suggested to fulfil this resolution. Dr. Diercks and ACEP staff will consult with Dr. Finnell to get his perspective on the ACEP Board’s request before a recommendation is made.